Join
Live feed
·
PRReleasevia Quantisnow
Silexion Therapeutics Corp logo

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany's BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

ByQuantisnow·Wall Street's wire, on your screen.
SLXN· Silexion Therapeutics Corp
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLXN (Silexion Therapeutics Corp) and more on Quantisnow.